{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:18:27Z","timestamp":1785907107966,"version":"3.56.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.008","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:21:54Z","timestamp":1704727314000},"page":"497-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Approach to High-Risk Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Xiaoyi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2023.12.008_bib1","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.16793","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.12.008_bib3","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","article-title":"Extramedullary disease in multiple myeloma","volume":"15","author":"Jagosky","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.hoc.2023.12.008_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib8","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.008_bib9","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.008_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.17670","article-title":"High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse","volume":"195","author":"Boyle","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.12.008_bib11","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.008_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2023.12.008_bib13","doi-asserted-by":"crossref","first-page":"101145","DOI":"10.1016\/j.beha.2020.101145","article-title":"Reconstructing the evolutionary history of multiple myeloma","volume":"33","author":"Maura","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.hoc.2023.12.008_bib14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-13-2159","article-title":"Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice","volume":"20","author":"Landgren","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib18","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib19","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk multiple myeloma: definition and management","volume":"17S","author":"Joseph","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2023.12.008_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","article-title":"Chromothripsis as a pathogenic driver of multiple myeloma","volume":"123","author":"Maura","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.hoc.2023.12.008_bib21","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.008_bib22","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib23","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A\u00a0compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A\u00a0high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib25","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib26","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1097\/HS9.0000000000000831","article-title":"Impact of ultra high-risk genetics on real-world outcomes of transplant-eligible multiple myeloma patients","volume":"7","author":"Panopoulou","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.hoc.2023.12.008_bib27","doi-asserted-by":"crossref","first-page":"e1198","DOI":"10.1259\/bjr\/52759767","article-title":"Assessing response of myeloma bone disease with diffusion-weighted MRI","volume":"85","author":"Messiou","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.hoc.2023.12.008_bib28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiol.13131529","article-title":"Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma","volume":"271","author":"Giles","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.hoc.2023.12.008_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib32","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma","volume":"23","author":"McDonald","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2023.12.008_bib34","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib35","doi-asserted-by":"crossref","first-page":"27854","DOI":"10.18632\/oncotarget.15718","article-title":"The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma","volume":"8","author":"Stein","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2023.12.008_bib36","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2023.12.008_bib38","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","article-title":"The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma","volume":"102","author":"Thanendrarajan","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2023.12.008_bib39","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/1078-0432.CCR-04-0467","article-title":"A\u00a0global expression-based analysis of the consequences of the t(4;14) translocation in myeloma","volume":"10","author":"Dring","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2162-3619-3-16","article-title":"Childhood B-acute lymphoblastic leukemia: a genetic update","volume":"3","author":"Woo","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.hoc.2023.12.008_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00018-022-04321-2","article-title":"The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors","volume":"79","author":"Topchu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.hoc.2023.12.008_bib42","doi-asserted-by":"crossref","first-page":"e1004566","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.hoc.2023.12.008_bib43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib44","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1158\/1078-0432.CCR-15-1790","article-title":"The spectrum and clinical impact of epigenetic modifier mutations in myeloma","volume":"22","author":"Pawlyn","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/epi.14.12","article-title":"Current and potential epigenetic targets in multiple myeloma","volume":"6","author":"Pawlyn","year":"2014","journal-title":"Epigenomics"},{"key":"10.1016\/j.hoc.2023.12.008_bib46","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s13046-021-02185-1","article-title":"Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer","volume":"40","author":"Ghamlouch","year":"2021","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib48","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41375-020-0742-z","article-title":"Multiple myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease","volume":"34","author":"Mason","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib49","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1186\/s12885-018-4602-4","article-title":"MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma","volume":"18","author":"Qiang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2023.12.008_bib50","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.008_bib51","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41375-019-0689-0","article-title":"Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma","volume":"34","author":"Maura","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2023.12.008_bib53","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib54","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1038\/bcj.2014.13","article-title":"Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients","volume":"4","author":"Walker","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib55","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib56","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib57","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2023.12.008_bib59","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.008_bib60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-019-0221-9","article-title":"Mutational processes contributing to the development of multiple myeloma","volume":"9","author":"Hoang","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib61","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.008_bib62","doi-asserted-by":"crossref","first-page":"13229","DOI":"10.18632\/oncotarget.3644","article-title":"Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma","volume":"6","author":"Cowan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2023.12.008_bib63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.hoc.2023.12.008_bib64","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood-2014-02-555755","article-title":"Jumping translocations and high-risk myeloma","volume":"123","author":"Morgan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib65","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2013-12-546077","article-title":"Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease","volume":"123","author":"Sawyer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib66","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in\u00a0situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-019-0226-4","article-title":"An acquired high-risk chromosome instability phenotype in multiple myeloma: jumping 1q syndrome","volume":"9","author":"Sawyer","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib69","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/leu.2016.370","article-title":"RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response","volume":"31","author":"Hofman","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib70","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.hoc.2023.12.008_bib72","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1158\/0008-5472.CAN-09-0773","article-title":"BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells","volume":"69","author":"Mani","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 Is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.008_bib74","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","article-title":"Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis","volume":"132","author":"Teoh","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib75","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/gcc.2","article-title":"MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy","volume":"57","author":"Samo","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.008_bib76","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","article-title":"Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma","volume":"29","author":"Boyle","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.008_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/mp.50.1.18","article-title":"p53 gene mutations in multiple myeloma","volume":"50","author":"Owen","year":"1997","journal-title":"Mol Pathol"},{"key":"10.1016\/j.hoc.2023.12.008_bib78","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2018-06-857250","article-title":"Subclonal TP53 copy number is associated with prognosis in multiple myeloma","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib79","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib81","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nri1203","article-title":"Plasma-cell homing","volume":"3","author":"Kunkel","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hoc.2023.12.008_bib82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-065X.2003.00041.x","article-title":"Homing of antibody secreting cells","volume":"194","author":"Cyster","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1016\/j.hoc.2023.12.008_bib83","doi-asserted-by":"crossref","first-page":"e1003323","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.hoc.2023.12.008_bib84","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib85","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib86","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hoc.2023.12.008_bib87","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.008_bib88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.hoc.2023.12.008_bib89","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T\u00a0cell landscape determines the response to bispecific T\u00a0cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.008_bib90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2023.12.008_bib91","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib92","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.008_bib93","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.12.008_bib94","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.008_bib95","doi-asserted-by":"crossref","first-page":"e046225","DOI":"10.1136\/bmjopen-2020-046225","volume":"11","author":"Brown","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.hoc.2023.12.008_bib96","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.008_bib97","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1038\/bcj.2017.12","article-title":"Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker","volume":"7","author":"Chavan","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.008_bib98","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.008_bib99","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T\u00a0cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.008_bib100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J\u00a0Hematol Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:20:24Z","timestamp":1760592024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001752"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to High-Risk Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}